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Abstract
Background: Biannual, mass azithromycin distribution has previously been shown to reduce all-cause child mortality
in sub-Saharan Africa. Subgroup analysis suggested that the strongest effects were in the youngest children, leading to
the hypothesis that targeting younger age groups might be an effective strategy to prevent mortality. We present the
methods of two randomized controlled trials designed to evaluate mass and targeted azithromycin distribution for the
prevention of child mortality in Burkina Faso, West Africa.
Methods/design: The Child Health with Azithromycin Treatment (CHAT) study consists of two nested, randomized
controlled trials. In the first, communities are randomized in a 1:1 fashion to biannual, mass azithromycin distribution or
placebo. The primary outcome is under-5 all-cause mortality measured at the community level. In the second, children
attending primary healthcare facilities during the first 5–12 weeks of life for a healthy child visit (e.g., for vaccination) are
randomized in a 1:1 fashion to a single orally administered dose of azithromycin or placebo. The primary outcome is
all-cause mortality measured at 6 months of age. The trial commenced enrollment in August 2019.
Discussion: This study is expected to provide evidence on two health systems delivery approaches (mass and targeted
treatment) for azithromycin to prevent all-cause child mortality. The results will inform global and national policies
related to azithromycin for the prevention of child mortality.
Trial registration: ClinicalTrials.gov, ID: NCT03676764. Registered on 19 September 2018; prospectively registered pre
results.
Background
Despite a secular trend of decreasing under-5 mortality
rate (U5MR) across sub-Saharan Africa, childhood mor-
tality remains persistently high in some regions [1]. The
development of innovative and scalable approaches for
reducing U5MR in high-burden regions is a priority.
The MORDOR study recently showed that biannual,
mass azithromycin distribution reduces all-cause child
mortality by 14% compared to placebo in districts in
Niger, Tanzania, and Malawi [2]. By far the largest ef-
fects were seen in Niger, which had the highest U5MR
of the three study sites, with nearly one in five deaths
averted. Mass drug administration with azithromycin
has been used by trachoma control programs for de-
cades [3] and is highly effective at clearing the ocular
strains of Chlamydia trachomatis that cause trachoma
[4, 5]. Mass azithromycin distribution for trachoma
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control has also been shown to reduce child mortality in
some settings [6, 7].
In the MORDOR study, the largest effects of azithro-
mycin treatment were in children aged 1–5 months old,
with a nearly 25% reduction in mortality in this sub-
group. MORDOR was a large simple trial [8], and was
not powered to detect differences in subgroup by age.
However, this result generated the hypothesis that treat-
ment of the youngest children may yield the greatest
benefit for prevention of mortality. Biannual mass distri-
bution of azithromycin is not efficient for reliably treat-
ing the youngest children, as, on average, children under
6 months of age in any given treatment phase are
reached at approximately 4 months of age. If treatment
of the youngest children proves to be the most effective
strategy for reducing mortality with azithromycin, alter-
native delivery mechanisms to mass distribution will
need to be identified.
Here, we describe two nested, randomized con-
trolled trials in which we evaluate the efficacy of tar-
geted azithromycin distribution in both the presence
and the absence of biannual mass azithromycin distri-
bution using a hierarchical factorial design [9]. We
evaluate the effect of azithromycin administered to in-
fants who are attending healthy child clinic visits dur-
ing their fifth through to their twelfth week of life,
compared to placebo on infant mortality rates. These
trials seek to determine (1) the efficacy of azithromy-
cin compared to placebo administered to young in-
fants for the prevention of infant mortality and (2)
the efficacy of biannual mass azithromycin distribution
to children aged 1–59 months compared to placebo
for reducing all-cause child mortality.
Methods/design
Study design
The Child Health with Azithromycin Treatment (CHAT)
study consists of two double-masked placebo-controlled,
nested, randomized trials (Fig. 1). In the first trial, com-
munities are randomized in a 1:1 fashion to biannual, dir-
ectly observed, orally administered, mass azithromycin or
biannual placebo distribution to children aged 1 to 59
months. In the second trial, individuals born into the com-
munities who are between 5 and 12 weeks of age are ran-
domized in a 1:1 fashion to a single dose of directly
observed, orally administered azithromycin or placebo
during a healthy child visit at a participating Centre de
Santé et de Promotion Sociale (CSPS). These are nurse-
led primary healthcare facilities that provide basic pre-
ventative and treatment services, including antenatal care,
postnatal care, and vaccination. The trial commenced en-
rollment in August 2019 and recruitment is expected to
last until late 2022. This protocol is reported according to
the Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) guidelines.
Objective and hypothesis
The objectives of this study are (1) to determine the effi-
cacy of biannual mass azithromycin distribution to chil-
dren aged 1–59 months on all-cause under-5 mortality
and (2) to determine the efficacy of a single targeted
dose of azithromycin administered during well-child
visits to children aged 5 to 12 weeks of age on 6-month
mortality. We hypothesize that biannual mass azithro-
mycin distribution will reduce all-cause child mortality
relative to placebo and that a single targeted dose of azi-
thromycin will reduce all-cause infant mortality relative
to placebo.
Study oversight
An independent Data and Safety Monitoring Committee
(DSMC) oversees the data collected in this study. The
DSMC contains members with expertise in pediatrics,
infectious disease, biostatistics, ethics, and mass azithro-
mycin distribution. The DSMC meets annually in a face-
to-face meeting, once before the study began and then
for ongoing monitoring annually. Quarterly phone meet-
ings are conducted to monitor progress of the trial, as
well as ad hoc meetings as needed. Study investigators
conduct monitoring visits to the study site at least bian-
nually. The principal investigators will notify the DSMC,
sponsors, and institutional review boards of any changes
in the study protocol and then will communicate
changes to study sites. Any deviations from trial proto-
cols are documented and reported as necessary.
Setting
This study is taking place in Nouna District in the Bou-
cle du Mouhoun region of northwest Burkina Faso
(Fig. 2). Burkina Faso is a landlocked country located in
francophone West Africa. The trial covers the area of
both the Nouna Health and Demographic Surveillance
Site (HDSS) [10], which covers approximately one third
of Nouna District, as well as the non-HDSS area. The
area is rural and agrarian, and most inhabitants are
farmers and cattle keepers [11]. The U5MR in Boucle du
Mouhoun was estimated at 110.8 per 1000 live births in
2015 [1].
Study development and community engagement
This study was developed in consultation with local,
national, and global policy-makers and stakeholders in
child health and survival. Community sensitization re-
lated to the study was done with leaders in each study
community. Local healthcare providers at each CSPS
were engaged prior to the start of the study, are kept in-
formed about study progress, and are involved in
Sié et al. Trials          (2019) 20:675 Page 2 of 9
informing potential participants about the study and fa-
cilitating follow-up.
Community recruitment
From November 2018 through March 2019, all commu-
nities in Nouna District were mapped. All communities
located in the district received permission from local
leaders to participate and have been included in the
study.
Individual recruitment
Children aged 28 days of age and older are recruited for
the study through well-child visits at the CSPSs in
Nouna District. Recruitment visits include village-based
recruitment days, vaccination visits (e.g., during the first
Expanded Program on Immunization visit which typic-
ally occurs between 6 and 8 weeks), postnatal care visits
(in the study area, a postnatal visit typically occurs at ap-
proximately 42 days of life), or any other well-child visit
that occurs during the early infancy period. To target
treatment as early as possible when the risk of mortality
is highest, we will attempt to enroll children under 56
days of age. Children will be eligible for inclusion in the
study if aged up to 84 days of life (12 weeks) at
enrollment.
Inclusion and exclusion criteria: communities
All communities in Nouna District with the exception of
Nouna Town are eligible for inclusion in the study, re-
gardless of size. Nouna Town is excluded because it is a
semi-urban community with lower mortality and greater
access to healthcare, and thus not comparable to the
rural communities that make up the remainder of the
district. To be eligible for the study, the community
leader must provide their consent for the community to
participate.
Inclusion and exclusion criteria: individuals
Due to the risk of infantile hypertrophic pyloric stenosis
(IHPS), children under 28 days of age are excluded from
the study [12]. Observational evidence has suggested that
macrolide use during the neonatal period may increase
the risk of IHPS [12, 13]. The safety and efficacy of macro-
lide use during the neonatal period for the prevention of
infant mortality is currently being tested in a concurrent
randomized controlled trial in Burkina Faso [14].
Randomization
The randomization list was developed by TCP and YL in
R version 3.5.1. Community randomization is stratified
by communities inside and outside the HDSS. Treat-
ment letters were randomly assigned to represent azi-
thromycin or placebo, and communities were randomly
assigned to a treatment letter using a masked random
seed value [15]. For individuals, study identification
numbers were assigned to a treatment letter (represent-
ing azithromycin or placebo) and pre-loaded into the
study application. During enrollment, the study applica-
tion displays the treatment letter associated with the
child’s identification number once the child is enrolled
in the study and the identification number has been
assigned.
Census
In all study communities, a door-to-door enumerative
census is conducted every 6 months (Fig. 3a). The
Fig. 1 Study flow diagram for the Child Health with Azithromycin Treatment (CHAT) study in Nouna District, Burkina Faso, West Africa. This study
is a hierarchical factorial study in which communities are randomized to biannual, mass, single-dose azithromycin or placebo distribution to all
children aged 1–59 months and infants aged 5–12 weeks are individually randomized to a single dose of azithromycin or placebo. Abbreviations:
MDA mass drug administration, CSPS Centre de Santé et de Promotion Sociale (primary healthcare facility)
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Fig. 2 Study area in Nouna District, Burkina Faso, West Africa. The shaded area indicates the Nouna Health and Demographic Surveillance site area of Nouna
District. Primary health facilities are indicated with red crosses. Abbreviations: HDSS Health and Demographic Surveillance Site, NIG-GIS geographic
information system
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census focuses specifically on children aged under 5
years who are living in the household. For each child, in-
formation is collected on their vital status (died, alive, or
moved). The census is conducted prior to treatment.
Community-based treatment and masking
Following each biannual census, children aged 1–59
months are treated with a single, directly observed 20-mg/
kg dose of orally administered azithromycin as a pediatric
suspension, identical to that used in trachoma control
programs [3, 16]. Those who are able to stand are
measuring using a height stick, identical to that used in
the trachoma control program in Burkina Faso, and dosed
accordingly. Children who are too young to stand are
weighed using a hanging scale. During randomization,
each community was randomly assigned a treatment letter
that corresponds to either azithromycin or placebo. Each
community is treated with bottles labeled with the
corresponding treatment letter. With the exception of the
treatment letter on the label, the azithromycin and
placebo and their labels and bottles are identical in
appearance. Participants, treatment workers, outcome
Fig. 3 Study assessments for community randomization (a) and individual randomization (b)
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assessors, and investigators are masked to community
treatment assignment.
Individual treatment and masking
Children recruited and enrolled in the individual study
will be treated with a single, directly observed, orally ad-
ministered, 20-mg/kg dose of azithromycin. After enroll-
ment in the study, each child is assigned a treatment letter
that will correspond to either azithromycin or placebo.
Treatment bottles are marked with treatment letters but
are otherwise identical in appearance. Participants, study
staff, and investigators are masked to individual treatment
assignment.
Data collection and management
Electronic data are captured in the field using the Survey-
Solutions platform (World Bank Group, Washington, DC,
USA).
Individual follow-up
Infants enrolled in the individual treatment trial will be
followed at 180 days (Fig. 3b). An additional visit at 14
days is conducted in a random sample of 10% of chil-
dren for adverse event screening. The primary outcome
visit is the 180-day visit. The location of residence and
at least one phone number (if available) are collected for
the caregiver of each child enrolled in the study. Care-
givers of study participants receive follow-up reminders
from study personnel, and if they do not attend a follow-
up visit in the healthcare facility, a home visit is
attempted.
Primary outcome measurement: community
The primary outcome of the community-randomized
portion of the study is all-cause mortality per the census.
To count towards the primary outcome, children must
be counted on one census and recorded as having died
in a subsequent census.
Primary outcome measurement: individual
The primary outcome for individually randomized chil-
dren is mortality at the 180-day visit. Mortality is mea-
sured via vital status assessment (categorized as alive,
died, moved, or unknown).
Secondary outcome measures: community
In a subset of 48 communities within the HDSS (“mortal-
ity-plus communities”), samples are taken from a
population-based random sample of 15 children aged
1–59months per community at 0 and 36months. Samples
include rectal swabs for the assessment of the intestinal
microbiome [17–19], nasopharyngeal swabs for the
assessment of macrolide resistance in commensal
pneumococcus, dried-blood-spot collection for assessment
of serologic markers of exposure to pathogens, and thin
and thick smears for malaria.
Secondary outcome measures: individual
Anthropometric measurements are recorded for all indi-
viduals at baseline and the 180-day visit, including
weight, height, and mid-upper-arm circumference.
Passive surveillance
Passive surveillance is undertaken at all CSPSs in the
study catchment area. During the study period, health-
care visits including reasons for the visit, diagnosis, and
treatment plan are recorded for children under 59
months of age. These data are linked to the community
and to individual children via recording the community
in which the child resides and the child’s study identifi-
cation number in the electronic data collection applica-
tion. Participation in the trial will not require alteration
to usual care pathways or use of any medications should
children need care during the course of the trial. Usual
care will continue for both arms of the trial, and because
the study is masked, we do not anticipate differential ac-
cess to care in children receiving azithromycin compared
to placebo. Because the trial is enrolling healthy partici-
pants, there are no anticipated harms or provisions for
post-trial care.
Adverse events
An adverse event survey is conducted among all children
aged 1–5 months in the 48 mortality-plus communities
approximately 2 weeks following treatment. Similarly,
caregivers of a random sample of 10% of individually
randomized children will be interviewed for adverse
events 2 weeks after treatment. Previous evidence from
MORDOR showed no evidence of a difference in safety
events in infants receiving azithromycin compared to
placebo, and the most common adverse events were
gastrointestinal, with a decrease in caregiver-reported
diarrhea in children receiving azithromycin compared to
placebo [20]. As in MORDOR, adverse event screening
in CHAT is designed for detection of a safety signal ra-
ther than to identify every adverse event in the study
population due to the scale of the study and excellent
safety profile of azithromycin for children in MORDOR
and trachoma control settings [21, 22].
Interim analysis: community
A single pre-specified interim analysis for efficacy will be
conducted when mortality data are available for the first
year (two study phases). The interim analysis will use an
alpha of 0.001, and the final analysis will be conducted
at an alpha of 0.049.
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Interim analysis: individual
A single pre-specified interim analysis for efficacy will be
conducted when mortality data are available for one full
year of recruitment (e.g., 18 months after the start of the
trial). The interim analysis will use an alpha of 0.001,
and the final analysis will be conducted at alpha 0.049.
Statistical analysis
The primary analyses for community randomization and in-
dividual randomization are pre-specified to be conducted
separately, with a secondary analysis planned to evaluate any
interaction due to the factorial design of the trial. Mortality is
a rare event, and the study is not powered to detect an inter-
action between the two interventions [8]. We note that the
existence of the two co-interventions is an external, not an
internal, validity concern, and results will be interpreted in
the context of the other azithromycin intervention. All ana-
lyses will be conducted as intention-to-treat.
Statistical analysis: community
The primary analysis will be conducted as negative bino-
mial regression. The number of person-years for persons
in the target age range will be derived by summing the
person-time for each study phase. The community-level
predictor will be treatment arm of the community. Due
to the cluster randomized nature of the study, primary
analyses for efficacy will be conducted at the cluster
level. Statistical significance will be assessed by permuta-
tion testing at the level of the randomization unit, with a
P value threshold for statistical significance of 0.049 (see
“Interim analysis”).
Statistical analysis: individual
The primary analysis will be conducted as a binomial re-
gression with a complementary log-log link. This model
estimates the relative hazard of mortality in children re-
ceiving azithromycin compared to placebo and allows
for varying person-time to be contributed by different
individuals. The analysis will be conducted at the level of
the individual. Statistical significance will be assessed by
permutation test, with a P value threshold for statistical
significance of 0.049 (see “Interim analysis”).
Statistical analysis: factorial design
As a pre-specified secondary analysis, we will assess
interaction between the community and individual azi-
thromycin interventions. The factorial analysis will be
conducted at the individual level using a binomial re-
gression model with a complementary log-log link, with
standard errors adjusted for clustering at the level of the
community. The model with include terms for the indi-
vidual and community randomization and the inter-
action term for the two interventions.
Sample size considerations: community randomization
The sample size calculation for the community trial is
based on the primary outcome, all-cause mortality as
measured by the census and is calculated based on the
number of randomization units (communities) in the
study area (N = 341), which was determined during the
pre-study mapping. We assume a rate of 20 deaths per
1000 person-years in children aged 1–59months, based
on previous studies in Niger [2] and data from the
Nouna HDSS [10]. The coefficient of variation was esti-
mated from the MORDOR-Niger study as 0.34, that the
average community size was 1000 people, and that
16.7% of the population is in the target age rage (1–59
months). Under these assumptions the inclusion of 341
clusters (170 and 171 per arm) would yield at least 80%
power to detect a difference in mortality of 13.65% with
a two-sided alpha of 0.05. We anticipate that approxi-
mately 450,000 treatments will be administered over the
36-month study.
Sample size considerations: individual randomization
The sample size calculation for the individual trial is
based on the primary outcome, all-cause mortality at 6
months of age in individuals. We assume that mortality
from 1 to 6 months is 40 deaths per 1000 live births and
loss to follow-up will be 5%. A sample size of 32,702 in-
fants (16,351 per arm) would provide at least 80% power
to detect a 15% difference in the probability of mortality.
Dissemination plan
The results of this study will be presented and local, na-
tional, and international meetings. The results will be
presented to key stakeholders in Burkina Faso and else-
where, including to the Ministry of Health in Burkina
Faso. The results will also be published in an open-
access format in peer-reviewed journals. Primary ana-
lyses for community and individual randomization will
be published separately.
Discussion
The MORDOR study demonstrated that biannual mass
azithromycin distribution reduces all-cause child mortal-
ity in some settings [2, 23]. This study led to considering
the inclusion of mass drug administration with azithro-
mycin for child mortality in World Health Organization
guidelines in regions with very high child mortality. The
mechanism behind this effect on mortality is unknown,
although presumably is via a reduction of the infectious
burden [24]. Although evidence of child mortality in
trachoma programs generally corroborates the findings
in MORDOR [6, 7, 25], when and where azithromycin
will be effective for reducing child mortality remains un-
known. MORDOR was a large simple trial with a rare
outcome (mortality), and thus the detection of effect
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modification by geography was difficult [26, 27]. Although
there was no significant difference in mortality rates by
study country, the study was not specifically designed to
detect differences between countries. The CHAT study
will provide evidence of the efficacy of biannual mass drug
administration with azithromycin for the prevention of
child mortality in a different time and place than MOR-
DOR, but in a region with child mortality rates that are
nearly as high as those in the Niger site of MORDOR.
Although subgroup analysis of MORDOR suggested that
the greatest effects were in younger (1–5-month-old) chil-
dren, there was no significant difference in the efficacy
across subgroups. This finding led to the hypothesis that
targeting younger children may be an efficacious approach
to preventing mortality. This study investigates an alterna-
tive health system delivery approach – distribution of azi-
thromycin during early well-child visits that are well
established in the health system. We anticipate that this
study will provide evidence both of the efficacy of targeting
azithromycin to young infants as well as the efficiency of in-
tegrating azithromycin into child health visits at healthcare
facilities. Several other ongoing studies are currently investi-
gating applications of azithromycin for child health. For ex-
ample, the ABCD study (ClinicalTrials.gov, ID:
NCT03130114) is a multisite, individually randomized study
investigating the efficacy of azithromycin compared to pla-
cebo on 6-month mortality in children under 2 years of age
who are recovering from an acute diarrheal episode. The
Toto Bora trial (ClinicalTrials.gov NCT02414399) is evalu-
ating the efficacy of a 5-day course of azithromycin on post-
discharge mortality in children aged 1–59months who had
been previously hospitalized [28]. The PregnAnZI-2 study
(ClinicalTrials.gov NCT03199547) is evaluating the efficacy
of maternal azithromycin administration on neonatal sepsis.
The results of the CHAT study will, therefore, become
available in the context of other studies that are testing azi-
thromycin in similar applications. Taken together, we an-
ticipate that these studies will yield a wealth of evidence
related to the role of azithromycin for child health via mul-
tiple potential delivery pathways and health conditions.
Evidence from trachoma control studies has generally
shown that mass azithromycin distribution for trachoma
control selects for macrolide resistance in some organisms
[29]. In MORDOR, communities receiving azithromycin
had a higher prevalence of macrolide resistance in
pneumococcal isolates and also showed evidence of ex-
pansion of the resistome [30]. Through the collection of
nasopharyngeal and rectal samples in the mortality-plus
communities of CHAT, we will build on this work by
evaluating antimicrobial resistance in macrolides and
other antibiotic classes in communities receiving
azithromycin and placebo for 36months. Given that azi-
thromycin will be given to approximately half of young in-
fants in the study communities, antimicrobial resistance
data from the placebo communities will provide some evi-
dence of macrolide resistance in communities where chil-
dren are being treated at an individual level.
There are several limitations to the design of this study
to consider. First, the scale of a study required to evaluate
a rare endpoint, such as mortality, is very large. The large,
logistically complicated scale of the studies requires that
the study be designed and conducted as a “large simple
trial” [8]. These trials improve efficiency by reducing the
complexity of a trial’s design. Large simple trials have very
simple inclusion criteria and simple outcome assessment
methods, often measuring few secondary endpoints. While
such steps are necessary to achieve the sample size re-
quired for the trial to be adequately powered, the number
of additional outcomes measured is limited. The multi-
level factorial design of the study means that there are no
communities in which some azithromycin is not being
distributed (e.g., placebo communities will have children
receiving azithromycin during well-child visits). While this
allows for assessment of the health facility intervention in
the presence of community azithromycin versus placebo,
there is no pure comparison group. Additional future
planned studies will evaluate mass distribution of azithro-
mycin in settings other than MORDOR and include pure
placebo communities. This study will answer similar, but
subtly different, research questions about azithromycin
implementation for child mortality.
Conclusions
The results of this study are expected to provide evidence
of the efficacy of mass and targeted azithromycin distribu-
tion for the prevention of child mortality. This will inform
policy about different health system approaches for deliv-
ering azithromycin, as well as providing evidence of its ef-
ficacy in a different population several years after
completion of the first MORDOR study. If proven to be
effective, the results of this study could lead to policies
recommending integration of azithromycin in primary
healthcare facilities, either as a standalone intervention or
in conjunction with mass azithromycin distribution.
Trial status
This protocol is version 2.9, 7 May 2019. Recruitment
began on 1 August 2019 and is expected to last until ap-
proximately 31 July 2022.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
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Sié et al. Trials          (2019) 20:675 Page 8 of 9
Abbreviations
CHAT: Community Health with Azithromycin Treatment; CSPS: Centre de
Santé et de Promotion Sociale; DSMC: Data and Safety Monitoring Committee;
HDSS: Health and Demographic Surveillance Site; IHPS: Infantile hypertrophic
pyloric stenosis; U5MR: Under-5 mortality rate
Authors’ contributions
AS, MO, MB, CB, BC, VB, EL, JMB, YL, TB, TCP, TD, TML, and CEO conceived
and designed the study. AS, CB, JMB, and CEO created the tables and
figures. CEO wrote the first draft of the manuscript. AS, MO, MB, CB, BC, VB,
EL, JMB, YL, TB, TCP, TD, TML, and CEO read and critically revised the
manuscript. All named authors adhered to the authorship guidelines for
Trials and have agreed to publication. No professional writers were involved
in this manuscript.
Funding
The CHAT study is funded by the Bill and Melinda Gates Foundation. CEO
and TD are supported by career development awards from Research to
Prevent Blindness. The funders had no role in design of the study or
decision to publish the study protocol.
Availability of data and materials
Not applicable. Upon completion of the trial, de-identified data will be made
publicly available per the Bill and Melinda Gates Foundation policy.
Ethics approval and consent to participate
This study was reviewed and approved by the Institutional Review Board at
the University of California, San Francisco (Protocol #17–24230) and the
Comité National d’Ethique pour la Recherche (National Ethics Committee of
Burkina Faso; Protocol #2018–8-111). Written informed consent to participate
is obtained from the caregiver of each child. The consent document
includes provisions for banking de-identified samples and sharing of de-
identified participant data. Sample informed consent documents can be
found in Additional file 2.
Consent for publication
Not applicable
Competing interests
The authors declare that they have no competing interests.
Author details
1Centre de Recherche en Santé de Nouna, Nouna, Burkina Faso. 2Francis I.
Proctor Foundation, University of California, 513 Parnassus Ave, Room S334,
San Francisco, CA, USA. 3Heidelberg Institute of Global Health (HIGH),
Heidelberg, Germany. 4Africa Health Research Institute (AHRI), Somkhele,
South Africa. 5Department of Global Health and Population, Harvard T.H.
Chan School of Public Health, Boston, MA, USA. 6Department of
Ophthalmology, University of California, San Francisco, CA, USA. 7Department
of Epidemiology and Biostatistics, University of California, San Francisco, CA,
USA.
Received: 17 August 2019 Accepted: 25 October 2019
References
1. Golding N, Burstein R, Longbottom J, et al. Mapping under-5 and neonatal
mortality in Africa, 2000–15: a baseline analysis for the Sustainable
Development Goals. Lancet. 2017;390:2171–82.
2. Keenan JD, Bailey RL, West SK, et al. Mass azithromycin distribution for reducing
childhood mortality in sub-Saharan Africa. N Engl J Med. 2018;378:1583–92.
3. Emerson PM, Hooper PJ, Sarah V. Progress and projections in the program
to eliminate trachoma. PLoS Negl Trop Dis. 2017;11:e0005402–4.
4. Chidambaram JD, Alemayehu W, Melese M, et al. Effect of a single mass
antibiotic distribution on the prevalence of infectious trachoma. JAMA.
2006;295:1142–6.
5. Solomon AW, Holland MJ, Alexander NDE, et al. Mass treatment with single-
dose azithromycin for trachoma. N Engl J Med. 2004;351:1962–71.
6. OBrien KS, Cotter SY, Amza A, et al. Childhood mortality after mass
distribution of azithromycin. Pediatr Infect Dis J. 2018;37:1082–6.
7. Porco TC, Gebre T, Ayele B, et al. Effect of mass distribution of azithromycin for
trachoma control on overall mortality in Ethiopian children: a randomized trial.
JAMA. 2009;302:962–8.
8. Yusuf S, Collins R, Peto R. Why do we need some large, simple trials? Stat
Med. 1984;3:409–20.
9. Arnold BF, Hogan DR, Colford JM, Hubbard AE. Simulation methods to
estimate design power: an overview for applied research. BMC Med Res
Methodol. 2011;11:94.
10. Sie A, Louis VR, Gbangou A, et al. The Health and Demographic Surveillance System
(HDSS) in Nouna, Burkina Faso, 1993–2007. Glob Health Action. 2010;3:5284.
11. Sie A, Tapsoba C, Dah C, et al. Dietary diversity and nutritional status among
children in rural Burkina Faso. Int Health. 2018;382:426–7.
12. Eberly MD, Eide MB, Thompson JL, Nylund CM. Azithromycin in early
infancy and pyloric stenosis. Pediatrics. 2015;135:483–8.
13. Lund M, Pasternak B, Davidsen RB, et al. Use of macrolides in mother and
child and risk of infantile hypertrophic pyloric stenosis: nationwide cohort
study. BMJ. 2014;348:g1908.
14. Sie A, Bountogo M, Nebie E, et al. Neonatal azithromycin administration to
prevent infant mortality: study protocol for a randomized controlled trial.
BMJ Open. 2019;9:e031162.
15. Porco TC, Stoller NE, Keenan JD, Bailey RL, Lietman TM. Public key
cryptography for quality assurance in randomization for clinical trials.
Contemp Clin Trials. 2015;42:167–8.
16. Taylor HR, Burton MJ, Haddad D, West F, Wright H. Trachoma. Lancet. 2014;
384:2142–52.
17. Doan T, Arzika A, Ray KJ, et al. Gut microbial diversity in antibiotic-naïve
children after systemic antibiotic exposure: a randomized controlled trial.
Clin Infect Dis. 2017;64:1147–53.
18. Doan T, Hinterwirth A, Arzika AM, et al. Mass azithromycin distribution and
community microbiome: a cluster-randomized trial. Open Forum Infect Dis.
2018;5:ofy182.
19. Oldenburg CE, Sie A, Coulibaly B, et al. Effect of commonly-used pediatric
antibiotics on gut microbial diversity in preschool children in Burkina Faso:
a randomized clinical trial. Open Forum Infect Dis. 2018;5:ofy289.
20. Oldenburg CE, Arzika AM, Maliki R, et al. Safety of azithromycin in infants
under six months of age in Niger: a community randomized trial. PLoS Negl
Trop Dis. 2018;12:e0006950.
21. Ayele B, Gebre T, House JI, et al. Adverse events after mass azithromycin
treatments for trachoma in Ethiopia. Am J Trop Med Hyg. 2011;85:291–4.
22. Astale T, Sata E, Zerihun M, et al. Self-reported side effects following mass
administration of azithromycin to eliminate trachoma in Amhara, Ethiopia:
results from a region-wide population-based survey. Am J Trop Med Hyg.
2019;100:696–9.
23. Keenan JD, Arzika AM, Maliki R, et al. Longer-term assessment of
azithromycin for reducing childhood mortality in Africa. N Engl J Med. 2019;
380:2207–14.
24. Arzika AM, Maliki R, Boubacar N, et al. Biannual mass azithromycin
distributions and malaria parasitemia in pre-school children in Niger: a
cluster-randomized, placebo-controlled trial. PLoS Med. 2019;16:e1002835.
25. Oldenburg CE, Arzika AM, Amza A, et al. Mass azithromycin distribution to
prevent childhood mortality: a pooled analysis of cluster randomized trials.
Am J Trop Med Hyg. 2019;100:691–5.
26. Porco TC, Oldenburg CE, Arzika AM, et al. Efficacy of mass azithromycin
distribution for reducing childhood mortality across geographic regions. Am
J Trop Med Hyg. 2019; Epub ahead of print.
27. Oron AP, Burstein R, Mercer LD, et al. Effect modification by baseline
mortality in the MORDOR azithromycin trial. Am J Trop Med Hyg. 2019;
Epub ahead of print.
28. Pavlinac PB, Singa BO, John-Stewart GC, et al. Azithromycin to prevent post-
discharge morbidity and mortality in Kenyan children: a protocol for a
randomised, double-blind, placebo-controlled trial (the Toto Bora trial). BMJ
Open. 2017;7:e019170.
29. O’Brien K, Emerson P, Hooper PJ, et al. Antimicrobial resistance following
mass azithromycin distribution for trachoma: a systematic review. Lancet
Infect Dis. 2018;S1437-3099:30444.
30. Doan T, Arzika AM, Hinterwirth A, et al. Macrolide resistance in MORDOR
I—A cluster-randomized trial in Niger. N Engl J Med. 2019;380:2271–3.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Sié et al. Trials          (2019) 20:675 Page 9 of 9
